The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients
A decision analytic model
Katerina Tori, ScB, Giannoula S. Tansarli, MD, Diane M. Parente, PharmD, Markos Kalligeros, MD, Panayiotis D. Ziakas, MD, PhD, Eleftherios Mylonakis, MD, PhD

Abstract
Purpose: Febrile neutropenia has a significant clinical and economic impact on cancer patients. This study evaluates the cost-effectiveness of different current empiric antibiotic treatments.

Methods: A decision analytic model was constructed to compare the use of cefepime, meropenem, imipenem/cilastatin, and piperacillin/tazobactam for treatment of high-risk patients. The analysis was performed from the perspective of U.S.-based hospitals. The time horizon was defined to be a single febrile neutropenia episode. Cost-effectiveness was determined by calculating costs and deaths averted. Cost-effectiveness acceptability curves for various willingness-to-pay thresholds (WTP) were used to address the uncertainty in cost-effectiveness.

Results: The base-case analysis results showed that treatments were equally effective but differed mainly in their cost. In increasing order: treatment with imipenem/cilastatin cost $52,647, cefepime $57,270, piperacillin/tazobactam $57,277, and meropenem $63,778. In the probabilistic analysis, mean costs were $52,554 (CI: $52,242-$52,866) for imipenem/cilastatin, $57,272 (CI: $56,978-$57,611) for cefepime, $57,294 (CI: $56,978-$57,611) for piperacillin/tazobactam, and $63,690 (CI: $63,370-$64,009) for meropenem. Furthermore, with a WTP set at $0 to $50,000, imipenem/cilastatin was cost-effective in 66.2% to 66.3% of simulations compared to all other high-risk options.

Discussion: Imipenem/cilastatin is a cost-effective strategy and results in considerable health care cost-savings at various WTP thresholds. Cost-effectiveness analyses can be used to differentiate the treatments of febrile neutropenia in high-risk patients.

Abbreviations: AKI = acute kidney injury, CI = confidence interval, ESMO = European Society for Medical Oncology, FN = febrile neutropenia, IDSA = Infectious Diseases Society of America, LOS = length of stay, MASCC = Multinational Association for Supportive Care in Cancer, NCCN = National Comprehensive Cancer Network, WTP = willingness to pay.

Keywords: antipseudomonal beta-lactams, cost-effectiveness, empirical treatment, febrile neutropenia, hematological malignancies, solid tumors

1. Introduction

Cytotoxic chemotherapy suppresses the hematopoietic system, often impairing host protection and defense mechanisms. Severe neutropenia results in patients with a neutrophil count less than 500 cells/mm³. Since the neutrophil-mediated component of the inflammatory response is attenuated, fever may be the earliest indication of infection. Febrile neutropenia (FN) incidence is over 60,000/year in the U.S. It encompasses a spectrum of disease severity from low- to high-risk patients, and mortality rates range from 2% to 20%. Furthermore, the mean cost of FN treatment in high-risk patients is estimated to be $105,944, including
This study aims to provide a comprehensive cost-effectiveness analysis of empirical antibiotics (cefepime, meropenem, imipenem/cilastatin, and piperacillin-tazobactam) recommended by the IDSA, ESMO and NCCN for the treatment of FN in high-risk patients.

2. Methods

2.1. Model structure

A decision-analytic model was constructed to assess the cost-effectiveness of various antibiotics used for empirical treatment of high-risk FN (Fig. 1). The analysis was performed from the perspective of U.S.-based hospitals. Subsequently, we relied on U.S. sources to assign costs. The time horizon for this analysis was...
was a single FN episode. The clinical progression of the disease guided our models structure. After empirical therapy initiation, patients were evaluated at 72 hours and end-of-treatment for death or survival, and treatment modification. Outcomes and costs were calculated from the time a patient was admitted to discharge or death. The analytical model was developed by using TreeAge Pro 2019 modeling software (TreeAge, Williamstown, MA). This study did not require IRB approval. An impact Table 1

| Input                                | Mean base-case value (Range) | Type of distribution (range/parameters) | Source |
|--------------------------------------|-----------------------------|----------------------------------------|--------|
| **Probabilities**                    |                             |                                        |        |
| Success                              |                             |                                        |        |
| Cefepime                             | 0.54 (0.39, 0.69)           | Uniform (0.39, 0.69)                   | [31–38]|
| Imipenem/cilastatin                  | 0.65 (0.54, 0.75)           | Uniform (0.54, 0.75)                   | [37,38]|
| Meropenem                            | 0.46 (0.38, 0.55)           | Uniform (0.38, 0.55)                   | [38]   |
| Piperacillin/tazobactam              | 0.53 (0.41, 0.65)           | Uniform (0.41, 0.65)                   | [32,40]|
| Mortality                            |                             |                                        |        |
| Early death                          | 0.00 (0.00, 0.01)           | Uniform (0.00, 0.01)                   | [42,43]|
| Death post success                   | 0.01 (0.00, 0.05)           | Uniform (0.00, 0.04)                   | [43]   |
| Death post failure                   | 0.03 (0.01, 0.05)           | Uniform (0.01, 0.05)                   | [34]   |
| **Adverse events**                   |                             |                                        |        |
| Bacteremia                           |                             |                                        |        |
| Cefepime                             | 0.06 (0.00, 0.13)           | Uniform (0.00, 0.13)                   | [33]   |
| Imipenem/cilastatin                  | 0.07 (0.03, 0.17)           | Uniform (0.03, 0.17)                   | [41]   |
| Meropenem                            | 0.06 (0.00, 0.15)           | Uniform (0.00, 0.15)                   | [34]   |
| Piperacillin/tazobactam              | 0.04 (0.02, 0.08)           | Uniform (0.02, 0.08)                   | [32,40]|
| Clostridium difficile infection       |                             |                                        |        |
| Cefepime                             | 0.08 (0.04, 0.13)           | Uniform (0.04, 0.13)                   | [30,36]|
| Imipenem/cilastatin                  | 0.14 (0.04, 0.26)           | Uniform (0.04, 0.26)                   | [39]   |
| Meropenem                            | 0.18 (0.05, 0.36)           | Uniform (0.05, 0.36)                   | [39]   |
| Piperacillin/tazobactam              | 0.03 (0.00, 0.07)           | Uniform (0.00, 0.07)                   | [32,40]|
| Nephrotoxicity                       |                             |                                        |        |
| Cefepime                             | 0.01 (0.00, 0.02)           | Uniform (0.00, 0.02)                   | [35,54]|
| Imipenem/cilastatin                  | 0.01 (0.00, 0.02)           | Uniform (0.00, 0.02)                   | [35]   |
| Meropenem                            | 0.05 (0.01, 0.10)           | Uniform (0.01, 0.10)                   | [35]   |
| Piperacillin/tazobactam              | 0.01 (0.00, 0.05)           | Uniform (0.00, 0.05)                   | [35]   |
| **Modification with Glycopeptides**  |                             |                                        |        |
| Cefepime                             | 0.60 (0.38, 0.81)           | Uniform (0.38, 0.81)                   | [31–34,36]|
| Imipenem/cilastatin                  | 0.43 (0.11, 0.79)           | Uniform (0.11, 0.79)                   | [41,43]|
| Meropenem                            | 0.41 (0.19, 0.65)           | Uniform (0.19, 0.65)                   | [41,43]|
| Piperacillin/tazobactam              | 0.62 (0.41, 0.80)           | Uniform (0.41, 0.80)                   | [32,40]|
| **Modification with Antifungals**    |                             |                                        |        |
| Cefepime                             | 0.40 (0.18, 0.63)           | Uniform (0.18, 0.63)                   | [31–34,36]|
| Imipenem/cilastatin                  | 0.28 (0.17, 0.39)           | Uniform (0.17, 0.39)                   | [41,43]|
| Meropenem                            | 0.50 (0.23, 0.76)           | Uniform (0.23, 0.76)                   | [41,43]|
| Piperacillin/tazobactam              | 0.31 (0.08, 0.60)           | Uniform (0.08, 0.60)                   | [32,40]|
| **Hospital length of stay or treatment (in days)** |                     |                                        |        |
| LOS for early death                  | 3.45 (1.00, 4.00)           | Gamma (4.71, 13.80)                    | [42,43]|
| Successful Treatment LOS             | 11 (4, 33)                 | Gamma (5.18, 0.47)                     | [41]   |
| Failed Treatment LOS                 | 26.5 (25-27.3)             | Gamma (4779.02, 180.34)                | [41]   |
| Early Death DoT                      | 3.45 (1.00, 4.00)           | Gamma (4779.02, 180.34)                | [41]   |
| Successful Treatment DoT             | 11.00 (4.00, 33.00)         | Gamma (5.18, 0.47)                     | [41]   |
| Failed Treatment DoT                 | 26.50 (25.00-27.30)         | Gamma (4779.02, 180.34)                | [41]   |
| Vancornycin DoT                      | 12.00 (0.00, 14.00)         | Gamma (207.36, 17.28)                  | [61]   |
| Antifungal Treatment DoT             | 11.50 (7.50, 13.00)         | Gamma (157.39, 13.69)                  | [61]   |
| **COSTS (USD)**                      |                             |                                        |        |
| Cost of Cefepime/day                 | 76.98 (32.88, 121.08)       | Gamma (27.42, 0.36)                    | [66]   |
| Cost of Imipenem- cilastatin/day     | 101.04 (45.36, 156.72)      | Gamma (29.64, 0.29)                    | [66]   |
| Cost of Meropenem/day                | 140.60 (39.60, 241.59)      | Gamma (17.44, 0.12)                    | [66]   |
| Cost of Piperacillin-tazobactam/day  | 73.34 (36.48, 110.20)       | Gamma (35.63, 0.49)                    | [66]   |
| Cost of Glycopeptide/day             | 41.32 (26.64, 57.00)        | Gamma (62.50, 1.51)                    | [66]   |
| Cost of therapeutic drug level monitoring | 140.3 (70.2, 280.6)        | Gamma (16.01, 0.11)                    | [67]   |
| Cost of Antifungals/day              | 311.23 (278.63, 383.62)     | Gamma (316.35, 1.02)                   | [66]   |
| Hospitalization cost/day             | 2,976.68 (1,488.34-5,953.36)| Gamma (16.0, 0.01)                     | [69]   |
| C. difficile Cost                    | 12,553.63 (10,143.02-15,099.95) | Gamma (230.90, 1.01)                   | [59]   |
| Acute Kidney Injury Cost             | 5,211.21 (7,874.81-8,547.60) | Gamma (5362.38, 0.65)                  | [70]   |
| Bacteremia Cost                      | 23,464.58 (10,782.02-36,147.14) | Gamma (30.81, 0.0013)                  | [71]   |

DoT = duration of treatment, LOS = length of stay.
inventory is provided in the Supplemental Digital Material Table S1, http://links.lww.com/MD/E157.

2.2. Decision tree model
Cefepime, imipenem-cilastatin, meropenem, and piperacillin/tazobactam were included in the analysis. The aforementioned guidelines.[2,11,12] also recommend ceftazidime, however, it was not included in the analysis because of infrequent clinical use.[14,15] The primary outcomes were all-cause mortality and cost of selected treatments. Model parameters included treatment success/failure, modification with glycopeptides and antifungals, nephrotoxicity, Clostridioides (Clostridium) difficile infections, bacteremia, hospital length of stay (LOS) and duration of antimicrobial treatment.

Model parameters and inputs are detailed in Supplemental Materials (Digital Supplemental Material 1, pages 1-2, http://links.lww.com/MD/E156).

2.3. Outcome and data analysis
Regimens were presented from most to least cost-effective. Each strategies cost accounted for the costs of antibiotic treatment, hospitalization, C. difficile infections, breakthrough bacteremia, and nephrotoxicity, taken as cost of AKI. Cost-effectiveness was estimated for various cost-effectiveness thresholds. To account
for random variation in costs and outcome variables, and to evaluate the robustness of our results, we conducted both deterministic (one-way sensitivity) and probabilistic analyses. The incremental effectiveness difference was defined as number of deaths averted. The calculations required for costs are detailed in Digital Supplemental Material 1 page 3, http://links.lww.com/MD/E156. Detailed costs and doses of the included drugs are included in the Supplemental Digital Material Table S2, http://links.lww.com/MD/E158.

In one-way sensitivity analysis all variables were allowed to vary within a range of values summarized in Table 1. In the probabilistic model all variables were varied simultaneously. Uniform distributions accounted for probability variations, and gamma distributions for costs, as recommended previously.\textsuperscript{[16,17]} LOS was modeled by a gamma distribution to reflect the skewed distribution of the variable. For data provided as median and range, recommendations by Hozo et al were used to convert the median to mean values and the range to standard deviation values.\textsuperscript{[18]}

In the probabilistic analysis 10,000 simulations were run.\textsuperscript{[17]} A value from the base-case analysis was randomly selected for each variable every time. Resulting simulations were plotted on an incremental cost-effectiveness coordinate plane, where the x-axis represented incremental effectiveness (probability of survival) and the y-axis represented incremental cost (USD). Points located within the southeast quadrant of the graph were cost-effective and dominant.\textsuperscript{[19]} Cost-effectiveness acceptability curves assessed the cost-effectiveness for various WTP thresholds.\textsuperscript{[20]}

3. Results

The employed model probabilities and costs, as well as their distributions and their distribution parameters are summarized in Table 1. The results of the base-case analysis, including probability estimates, incremental costs and effectiveness values are summarized in Table 2.

3.1. Base-case analysis

The cost-effectiveness analysis suggested imipenem/cilastatin as the most cost-effective regimen. Costs are provided in increasing order. The base-case costs were $52,647 for imipenem/cilastatin, $57,270 for cefepime, $57,277 for piperacillin/tazobactam, and $63,778 for meropenem. At base-case all treatments were equally effective (0.97 probability of survival) as seen in Table 2.

![Graph](image-url)

Figure 2. (Continued)
3.2. One-way sensitivity analysis

The sensitivity analysis evaluated the impact of fluctuations in each variable within the ranges specified in Table 1. Each individual parameter value was evaluated independently, while all other stayed fixed at the base-case value. Results were robust to one-way sensitivity analysis, with only a few exceptions. Cefepime became dominant for a probability of success ≥0.63. Thus, in clinical situations where the probability of success with cefepime equals or surpasses 0.63, cefepime is favored in terms of cost-effectiveness. Furthermore, piperacillin/tazobactam became a dominant strategy, and thus favored in terms of cost-effectiveness, when LOS after successful treatment extended beyond 25.8 days.

3.3. Probabilistic sensitivity analysis

In probabilistic sensitivity analysis, all parameters can simultaneously depart from base-case values. In the probabilistic analysis, the mean cost was $52,554 (CI: $52,242-$52,866) for imipenem/cilastatin, $57,272 (CI: $56,951-$57,593) for cefepime, $57,294 (CI: $56,978-$57,611) for piperacillin/tazobactam, and $63,690 (CI: $63,370-$64,009) for meropenem. Incremental cost-effectiveness curves (Fig. 2), which aimed to show the uncertainty around the cost-effectiveness outcomes, demonstrate the uncertainty in estimates of cost-effectiveness for a WTP set from $0. Imipenem/cilastatin fell on the cost-saving and cost-effective fourth quadrant in 46.2% of simulations when compared to cefepime (Fig. 2a), 59.86% of simulations when compared to meropenem (Fig. 2b), 47.97% of simulations when compared to piperacillin/tazobactam (Fig. 2c).

Finally, the cost-effectiveness acceptability curves (Fig. 3), which show the probability that each strategy was cost-effective for various WTP thresholds, demonstrated that imipenem/cilastatin was cost-effective from 66.22% to 65.25% of simulations, cefepime was cost-effective from 19.11% to 19.14% of simulations, piperacillin/tazobactam was cost-effective from 14.62% to 14.56% of simulations, and meropenem was cost-effective in 0.05% of simulations for a WTP ranging from $0 to $50,000.

4. Discussion

Febrile neutropenia is a potentially life-threatening infection with high healthcare-associated costs. To date, there is no cost-
effectiveness analysis on empirical antibiotic selection for adult high-risk FN patients. We performed a decision analytic model to optimize selection between recommended drugs.\[^{2,11,12}\] Within the specified assumptions, the cost-effectiveness rankings showed that all regimens were equally effective at base-case, and imipenem/cilastatin had a lower cost, followed by cefepime, piperacillin/tazobactam, and meropenem. In the probabilistic analysis, imipenem/cilastatin outperformed competitors as first drug choice. Finally, imipenem-cilastatin remained dominant at different WTP thresholds.

The total cost of cancer-related FN hospitalizations in the U.S. was as high as $2.3 billion for adults in 2012 with a mean hospital cost of $24,770 per stay.\[^{21}\] To this effect, it is crucial to identify an antibiotic regimen that can both improve clinical outcomes and result in cost savings. Guidelines allow us to choose between the 4 different antimicrobial options based on the spectrum coverage of target infections.\[^{2,11,12}\] Although the effectiveness (probability of survival) of different strategies was equivalent, there was a considerable difference in cost. In this study, different success probabilities were the main contributor to cost. Imipenem/cilastatin had the highest success probability, and thus the lowest probability of failure. This translated to lower LOS for the majority of treated patients, and thus lower costs overall.

The cost of a FN episode in our model was approximately $53,000 when using imipenem/cilastatin. It did not include physician office services, chemotherapy, or outpatient hospital costs, which were included in the literature.\[^{9}\] Imipenem/cilastatin has been associated with statistically significant higher risk of any adverse event in the recently published meta-analysis by Horita et al, although those events did not lead to drug discontinuation.\[^{22}\] Notably, all adverse events, except for vomiting, nausea, and skin rash were included in our analyses.

Figure 3. Cost-effectiveness acceptability curves for various willingness-to-pay thresholds for high-risk patients. These curves show the percent of the 10,000 simulations at which each treatment strategy was cost-effective.
Interestingly, imipenem/cilastatin had higher success rates than meropenem in our analyses as seen in Table 1. Guidelines recommend imipenem/cilastatin and meropenem as first-line empirical treatments. A systematic review of 27 randomized controlled clinical trials comparing imipenem/cilastatin and meropenem, resulted in equal clinical and bacteriological effectiveness. Other studies showed that 1.5 g/day of imipenem/cilastatin was equivalent to 3 g/day of meropenem in clinical and bacteriological outcomes, and adverse events. The doses used in our analysis were in agreement with the recommendations (500 mg four times a day and 1 g three times a day for imipenem/cilastatin and 1 g 3 times daily for meropenem).

Economic analyses demonstrate that imipenem/cilastatin is more effective and less costly than meropenem in intra-abdominal infections. Lower dosage of imipenem used (500 mg four times a day vs 1 g three times a day for meropenem), may provide imipenem/cilastatin with a pharmacoeconomic advantage. Finally, imipenem/cilastatin has a superior (4 times) in vitro activity against gram-positive pathogens. It is therefore unclear to us why the probabilities of success of imipenem/cilastatin and meropenem were different in our analysis. However, evidence suggests that imipenem/cilastatin is generally superior to meropenem, especially in gram-positive infections.

Our results are compelling, but the study has some notable limitations. First, our analysis spanned a short time horizon limited to a single FN episode. Since cancer patients undergo multiple chemotherapy cycles, it is possible that they suffer from multiple FN episodes. This renders empirical antibiotic selection more complicated, when we consider prior isolation and infection data, resistance patterns, and cyclical use of broad-spectrum antibiotics. Thus, more episodes might become more complex, therefore leading to higher costs. Second, the included studies did not provide separate outcomes for patients with solid and hematological malignancies, despite their respective differences in FN. For example, the occurrence of FN in solid metastatic tumors is 10% to 50%, and can reach 80% in some hematological malignancies, notably acute leukemias. Furthermore, solid tumors and lymphomas usually have shorter duration of neutropenia after chemotherapy. Therefore, a different setting might be needed to account specifically for patients with acute leukemias and autologous stem cell transplantation, as protracted neutropenias and fever are more common.

In conclusion, our analysis suggests that there are significant cost-effectiveness differences between available empirical treatment for FN. Imipenem/cilastatin appears to be more cost-effective, but in specific populations (i.e., in patients that are likely to respond to cefepime, or those needing longer treatment) other approaches can be cost-effective. In an era of limited resources, future studies should include cost-effectiveness as a potential factor that might differentiate regimens. These cost-effectiveness studies could help personalize treatment for FN.

Author contributions

KT designed the study, performed the data collection and analysis, prepared tables and figures, participated in data interpretation, wrote and drafted the initial manuscript, and approved the final manuscript as submitted. Ms. Tori had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. GST, DMP, MK and PDZ designed the study, participated in data collection, extraction and interpretation, revised the manuscript, and approved the final manuscript as submitted. EM conceptualized and designed the study, interpreted the data, reviewed and revised the manuscript, and approved the final manuscript as submitted.

References

[1] Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–37.
[2] Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56–93.
[3] Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975;135:715–9.
[4] Gaggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916–24.
[5] Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res 2014;14:162.
[6] Kudrer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–66.
[7] Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010;116:5555–63.
[8] Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 0039;2013:92.
[9] Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809–23.
[10] Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038–51.
[11] NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer-Related Infections, version 1. 2019. National Cancer Comprehensive Network website. http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Published October 25, 2018. Accessed November 15, 2018.
[12] Averbuch D, Orash C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013;98:1826–35.
[13] Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82 Suppl:S105–17.
[14] Spanik S, Kruopova I, Trupl J, et al. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study, J Infect Chemother 1999;5:180–4.
[15] Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206–12.
[16] Briggs ACK, Sculptor M. Decision Modelling for Health Economic Evaluation. Oxford, United Kingdom: Oxford University Press; 2006.
[17] Ziakas PD, Zacharioudakis IM, Zervou FN, et al. Methicillin-resistant Staphylococcus aureus prevention strategies in the ICU: a clinical decision analysis. Crit Care Med 2015;43:382–93.
[18] Hozo SP, Djulbegovic B, Hozo L. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
[19] Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ 2004;13:405–15.
[20] Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106–8.
[39] Aparicio J, Oltra A, Llorca C, et al. Randomised comparison of monomodal beta-lactams for febrile neutropenia empiric therapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176–89.

[40] Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg Infect (Larchmt) 2005;6:329–43.

[41] Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176–89.

[42] Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486–94.

[43] Weycker D, Li X, Edelsberg J, et al. Risk and consequences of infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 2005;36:185–200.

[44] Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing imipenem/cilastatin (1.5g daily) versus meropenem (3.0g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997;29:503–8.

[45] Basoli A, Meli EZ, Mazzocchi P, et al. Imipenem/cilastatin (1.5g daily) versus meropenem (1.0g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 2005;38:265–70.

[46] Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients The Meropenem Study Group of Leuven, London and Nijmegen. J Antimicrob Chemother 1995;36:185–200.

[47] Holdt A, Mathu M, Hachanefoglu A. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia. Rev Esp Quimioter 2016;29:69–75.

[48] Harter C, Schulze B, Goldschmidt H, et al. Piperacillin-tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 2006;37:373–9.

[49] Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295–301.

[50] Goetschler M, Hahn C, Fiscon A, et al. Piperacillin-tazobactam is more effective than ceftazidime plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer 2003;11:362–70.

[51] Otzopark N, Fisnik N, Aydemir H, et al. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol 2010;40:761–7.

[52] Sipski OR, Arda B, Nazli-Zeka A, et al. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases. Int J Clin Pract 2014;68:230–5.

[53] Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 1998;76:73–80.

[54] Bokma W, Akan H, Korten V, et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. Int J Antimicrob Agents 1999;13:15–9.

[55] Jimeno A, Arcediano A, Bazares S, et al. Randomized study of ceftazidime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCT) with febrile neutropenia. Clin Transl Oncol 2006;8:889–95.

[56] Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1999;43:1336–41.

[57] Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992;30:843–54.

[58] Hess U, Bohne C, Rey K, et al. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998;6:402–9.

[59] Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283–91.

[60] Shah PM, Heller A, Fuhr HG, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996;24:480–4.

[61] Wrenn RH, Cluck D, Kennedy L, et al. Extended infusion compared to standard infusion ceftazidime as empiric treatment of febrile neutropenia. J Oncol Pharm Pract 2017;23:170–5.

[62] Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;43:697–704.

[63] Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391–402.
[63] Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282–9.

[64] Oyake T, Kowata S, Murai K, et al. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial. Eur J Haematol 2016;96:602–9.

[65] Jeong SH, Kim DY, Jang JH, et al. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. Ann Hematol 2016;95:337–44.

[66] IBM Micromedex Red Book (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/redbook.ModifyRedBookSearch Accessed on 03/25/2019.

[67] James CW, Gurk-Turner C. Recommendations for monitoring serum vancomycin concentrations. Proc (Bayl Univ Med Cent) 2001;14:189–90.

[68] The Kaiser Family Foundation State Health Facts, Data Source: 1999-2014 AHA Annual Survey, Copyright 2015 by Health Forum, LLC, an affiliate of the American Hospital Association. Available at: http://kff.org/health-costs/state-indicator/expenses-per-inpatient-day/?currentTimeframe=0&sortModel=%7B%22%22:22%22%22%22&Location%22,%22sort%22,%22asc%22%22%22%22%22. Lastly accessed on 9/17/2018.

[69] Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039–46.

[70] Silver SA, Long J, Zheng Y, et al. Cost of acute kidney injury in hospitalized patients. J Hosp Med 2017;12:70–6.

[71] Kilgore M, Brossette S. Cost of bloodstream infections. Am J Infect Control 2008;36: S172 e171-173.